Medical/Pharmaceuticals

Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding inthe Simultaneous Presence of PD-1 & VEGF Cooperative Binding of Ivonescimab Enables Higher Avidity in the Tumor Microenvironmentwith Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of VEGF in...

2023-11-02 20:00 713

European Medicines Agency validates Pierre Fabre Laboratories' marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC)

- BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) shows meaningful clinical benefit in adult patients with BRAFV600-mutant advanced NSCLC - The application is based on results from the PHAROS study,[1] which showed an objective response rate of 75% in treatment-naïve patients and 46% in previou...

2023-11-02 18:52 918

Cambrex Announces Sale of Drug Product Business Unit

EAST RUTHERFORD, N.J., Nov. 2, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), has today completed the sale of its Drug Product Business Unit toWilmington, Delaware based Noramco. Cambrex's Drug Product business provides product developme...

2023-11-02 18:00 1541

Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis

SHENZHEN, China, Nov. 2, 2023 /PRNewswire/ -- On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen" and with stock code 688321.SH) received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration ("NMPA") thro...

2023-11-02 15:58 1473

Xinhua Silk Road: 54th Zhangshu National Traditional Chinese Materia Medica Trade Fair kicks off in E. China's Jiangxi

BEIJING, Nov. 2, 2023 /PRNewswire/ -- The 54th Zhangshu National Traditional Chinese Materia Medica Trade Fair was held recently in Zhangshu, a county-level city in eastChina's Jiangxi Province. Photo shows the opening ceremony of the 54th Zh...

2023-11-02 14:21 2309

Myrkl - The NEW Liver Function and Detox Support Supplement that sold out in 24hrs

Enjoy socialising without sacrificing the next day! AUCKLAND, New Zealand, Nov. 2, 2023 /PRNewswire/ -- Myrkl (pronounced myr-a-kle)is the new liver function and detox support supplement that is taking the world by storm. This innovative supplement contains patented AB001™ which activates i...

2023-11-02 11:25 1725

Chula Launches the Latest Parkinson's Gloves to Reduce Tremors

BANGKOK, Nov. 2, 2023 /PRNewswire/ -- Chula   medical researchershave developed lightweight and easy-to-use Parkinson's gloves that can automatically reduce tremors, allowing Parkinson's Disease patients to enjoy social life and reducing side effects from medication an...

2023-11-02 10:00 1832

Precision, Effectiveness, and Intelligence: Explore the Latest Trend of Healthcare and Medical Equipment Industry at 134th Canton Fair

GUANGZHOU, China, Nov. 1, 2023 /PRNewswire/ -- As the public is paying increasing attention to health management, the 5-day onsite exhibition of Phase 3 of the 134th Canton Fair held from October 31st to November 4th will present nearly 600 quality exhibitors in medical and healthcare industries ...

2023-11-02 08:00 1774

TraceLink MINT Wins 2023 Pharma Innovation Award: 100% End-to-End Supply Chain Digitalization is Now Within Reach

100% End-to-End Supply Chain Digitalization is Now Possible with Proven Network Orchestration Capability BOSTON, Nov. 2, 2023 /PRNewswire/ -- TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than 291,000 healthcare and life...

2023-11-02 05:22 1787

Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

PALO ALTO, Calif., Nov. 1, 2023 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com ), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies based in Palo Alto, CA, and Heartseed Inc. ("Heartseed"), a Tokyo-based bio...

2023-11-02 00:00 1823

Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction

The Group is Advancing the Program to a Phase II Clinical Study Data presented at the 2023 Fall Clinical Dermatology Conference HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Nov. 1, 2023 /PRNewswire/ --Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries,...

2023-11-01 22:07 2256

Johnson & Johnson Innovation Launches Singapore QuickFire Challenge with the Singapore Economic Development Board

Following launch of first-of-its-kind collaboration between Johnson & Johnson Innovation – JLABS andSingapore's Economic Development Board, the Singapore QuickFire Challenge invites innovators to pitch for grant funding from a pool of $100,000 for further development. SINGAPORE, Nov. 1, 2023 /PRN...

2023-11-01 22:05 2151

Milliken & Company Launches OVIK Health

Company rebrands healthcare business as a strategic enabler SPARTANBURG, S.C., Nov. 1, 2023 /PRNewswire/ -- Today, global diversified manufacturer Milliken & Company unveiled a new brand platform for its healthcare business. OVIK Health, as Milliken Healthcare Products, LLC, will now be known, r...

2023-11-01 21:38 2388

AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023

* Six posters featuring the Lunit SCOPE suite and new insights into the tumor microenvironment are to be showcased at the SITC 2023 Annual Meeting SEOUL, South Korea, Nov. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therap...

2023-11-01 21:08 1774

Jolly Good Inc. Establishes North American Subsidiary: Joint Development of Medical VR for "Apple Vision Pro" with U.S. Experts

~ First Phase: Joint Development of Chronic Pain VR with U.S. Chronic Pain Experts TOKYO, Nov. 1, 2023 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as Jolly Good), which develops and provides medical VR, announces that it has established a North Ame...

2023-11-01 21:00 2008

SIBIONICS Achieves Milestone: Receiving CE Mark for Its Groundbreaking GS1 Continuous Glucose Monitoring System

SHENZHEN, China, Nov. 1, 2023 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, is delighted to announce that it has received the CE Mark for its revolutionary GS1 CGM. This significant milestone marks a momentous achievement for SIBIONICS, fac...

2023-11-01 20:28 3224

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunother...

2023-11-01 20:00 1605

CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China

* CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainlandChina. CStone to retain the rights to nofazinlimab outside mainland China. * This partnership will combine the strengths of CStone a...

2023-11-01 18:10 3432

AXA BetterMe Weekend concludes in high note, drawing over 12,000 participants

Two-day carnival inspires physical and mental well-being Allowing citizens to unwind and rejuvenate to become a BetterMe HONG KONG, Nov. 1, 2023 /PRNewswire/ -- AXA BetterMe Weekend, the iconic annual carnival hosted by AXA Hong Kong andMacau (AXA) on 28 and 29 October 2023, was a resounding succ...

2023-11-01 18:02 2163

Curocell Completes Korea's First Phase 2 Clinical Trial for Next-Generation CAR-T

* Anbal-cel targeting DLBCL completes phase 2 trial * Anticipation growing over Korea's first CAR-T therapy ahead of regulatory review * Commercial manufacturing scheduled in 2025 at Korea's only CAR-T GMP facility DAEJEON, South Korea, Nov. 1, 2023 /PRNewswire/ -- Curocell, South Korea ...

2023-11-01 16:23 1704
1 ... 142143144145146147148 ... 617